Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Analysis of Transcriptome, Mirnome and Genomic Profiles in Association with Clinical Outcome in a Prospective Series of Primary Plasma Cell Leukemia

Blood (2012) 120 (21): 3938.

https://doi.org/10.1182/blood.V120.21.3938.3938

Published: 2012

Journal Articles

A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide

Antonio Palumbo, MD, Alessandra Larocca, MD, Angelo Michele Carella, MD, Davide Rossi, Vittorio Montefusco, MD, Samantha Ferrari, MD, Alberto Santagostino, MD, Tommasina Guglielmelli, MD, Monica Galli, MD, Antonio Capaldi, MD, Nicola Giuliani, M.D., Ph.D., Giacinto La Verde, Paola Omedè, MD, Ileana Baldi, Mario Boccadoro, MD, Paolo Corradini, MD

Blood (2011) 118 (21): 632.

https://doi.org/10.1182/blood.V118.21.632.632

Published: 2011

Journal Articles

IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals

Marta Coscia, MD, PhD, Francesca Pantaleoni, PhD, Chiara Riganti, MD, Candida Vitale, MD, Micol Rigoni, PhD, Silvia Peola, PhD, Daniela Drandi, PhD, Barbara Castella, PhD, Marina Ruggeri, PhD, Paola Omedè, MD, Marco Ladetto, MD, Amalia Bosia, MD, Mario Boccadoro, MD, Massimo Massaia, MD

Blood (2010) 116 (21): 2431.

https://doi.org/10.1182/blood.V116.21.2431.2431

Published: 2010

Journal Articles

Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m 2 in Elderly Newly Diagnosed Patients: An Interim Analysis.

Antonio Palumbo, MD, Ilaria Avonto, MD, Francesca Patriarca, MD, Claudia Crippa, MD, Maria T. Petrucci, MD, Fausto Rossini, MD, Paolo Corradini, MD, Anna M. Liberati, MD, Nicola Giuliani, MD, Norbert Pescosta, MD, Patrizia Falco, MD, Alessandra Larocca, MD, Paola Omedè, MD, Massimo Offidani, MD, Renato Fanin, MD, Mario Boccadoro, MD

Blood (2007) 110 (11): 448.

https://doi.org/10.1182/blood.V110.11.448.448

Published: 2007

Journal Articles

A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m 2 (MEL200) Versus Melphalan 100 mg/m 2 (MEL100) in Newly Diagnosed Myeloma Patients.

Antonio Palumbo, MD, Sara Bringhen, MD, Maria Teresa Petrucci, MD, Antonietta Falcone, MD, Anna Marina Liberati, MD, Mariella Grasso, MD, Francesco Pisani, MD, Tommaso Caravita, MD, Patrizia Pregno, MD, Andrea Nozza, MD, Paola Omedè, MD, Patrizia Falco, MD, Pellegrino Musto, MD, Robin Foà, MD, Mario Boccadoro, MD

Blood (2006) 108 (11): 55.

https://doi.org/10.1182/blood.V108.11.55.55

Published: 2006

NARROW

Analysis of Transcriptome, Mirnome and Genomic Profiles in Association with Clinical Outcome in a Prospective Series of Primary Plasma Cell Leukemia

A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide

IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals

Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m 2 in Elderly Newly Diagnosed Patients: An Interim Analysis.

A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m 2 (MEL200) Versus Melphalan 100 mg/m 2 (MEL100) in Newly Diagnosed Myeloma Patients.

Email alerts

ASH Publications

American Society of Hematology

Analysis of Transcriptome, Mirnome and Genomic Profiles in Association with Clinical Outcome in a Prospective Series of Primary Plasma Cell Leukemia

A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide

IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals

Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m 2 in Elderly Newly Diagnosed Patients: An Interim Analysis.

A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m 2 (MEL200) Versus Melphalan 100 mg/m 2 (MEL100) in Newly Diagnosed Myeloma Patients.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only